Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Combo of Approved Agents Active in High-Risk Large B-Cell Lymphoma

2.

Elder Abuse: Red Flags to Look Out For While Receiving Care.

3.

Researchers can now forecast how prostate cancer bone metastases will react to radium-223 treatment.

4.

Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma

5.

Scientists pioneer noninvasive 3D imaging to enhance skin cancer management


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot